Andrew Hirsch is the founder of C4 Therapeutics. C4 Therapeutics has raised $170M in total funding. Latest round: Series B. Based in Watertown, MA.
Andrew Hirsch is the CEO of C4 Therapeutics, a clinical-stage biotechnology company focused on targeted protein degradation. He joined C4 in 2020, having previously served as an executive at Agios Pharmaceuticals. Prior to that, he led Bind Therapeutics.
Full founder directory · Investor directory · Company funding database · Fundraising library